🇺🇸 FDA
Pipeline program

BMN 333, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection, BMN 333

333-301

Phase 3 small_molecule active

Quick answer

BMN 333, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection, BMN 333 for Achondroplasia is a Phase 3 program (small_molecule) at BioMarin International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
BioMarin International Limited
Indication
Achondroplasia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials